Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05479994 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Study of BGB-11417 in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

StatusActive, Not Recruiting
PhasePhase 2
SponsorBeiGene
Started
View on ClinicalTrials.gov ↗

Record History

  1. Start date: Oct 24, 2022 to Oct 25, 2022v13
  2. Primary completion date changed from estimate of Apr 30, 2025 to Jan 24, 2025v12
  3. Study sites: 34 to 50v11
  4. Trial status: Recruiting to Active, Not Recruiting Enrollment target: estimated 97 to confirmed 100 · Study sites revised (34)v10 Show 2 more changesShow less
    • Enrollment target: estimated 97 to confirmed 100
    • Study sites revised (34)

    See this version in full on ClinicalTrials.gov ↗

  5. Enrollment target: 72 to 97 Study sites: 50 to 34 · Primary completion date: Nov 30, 2024 to Apr 30, 2025 · Completion date: Sep 15, 2027 to Aug 25, 2027 · 1 morev9 Show 4 more changesShow less
    • Study sites: 50 to 34
    • Primary completion date: Nov 30, 2024 to Apr 30, 2025
    • Completion date: Sep 15, 2027 to Aug 25, 2027
    • Secondary endpoints: details revised at 2 of 11 entries
Show 7 earlier versionsHide 7 earlier versions
  1. Study sites: 46 to 50v8
  2. Study sites revised (46) Eligibility criteria shortened, about 4 wordsv7 Show 1 more changeShow less
    • Eligibility criteria shortened, about 4 words

    See this version in full on ClinicalTrials.gov ↗

  3. Study sites: 42 to 46v6
  4. Study sites: 1 to 42v5
  5. Eligibility criteria shortened, about 4 wordsv4 See this version in full on ClinicalTrials.gov ↗
  6. Trial status: Not Yet Recruiting to Recruiting Study sites: 0 to 1 · Start date changed from estimate of Dec 15, 2022 to Oct 24, 2022v3 Show 2 more changesShow less
    • Study sites: 0 to 1
    • Start date changed from estimate of Dec 15, 2022 to Oct 24, 2022
  7. Start date: Sep 15, 2022 to Dec 15, 2022 Primary completion date: Sep 30, 2024 to Nov 30, 2024 · Completion date: Jan 30, 2025 to Sep 15, 2027 · Eligibility criteria shortened, about 97 words · 2 morev2 Show 5 more changesShow less
    • Primary completion date: Sep 30, 2024 to Nov 30, 2024
    • Completion date: Jan 30, 2025 to Sep 15, 2027
    • Eligibility criteria shortened, about 97 words
    • Secondary endpoints: details revised at 1 of 11 entries
    • Study title shortened, about 6 words

    See this version in full on ClinicalTrials.gov ↗

  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The purpose of this study is to evaluate the efficacy of BGB-11417 in participants with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL)
Trial Details
NCT Number NCT05479994
Lead Sponsor BeiGene
Conditions Leukemia, Lymphoma, Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Small Lymphocytic Lymphoma, Relapsed Chronic Lymphocytic Leukemia
Enrollment 100 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov